CN1268636C - 多拉司他汀15衍生物 - Google Patents

多拉司他汀15衍生物 Download PDF

Info

Publication number
CN1268636C
CN1268636C CNB988073595A CN98807359A CN1268636C CN 1268636 C CN1268636 C CN 1268636C CN B988073595 A CNB988073595 A CN B988073595A CN 98807359 A CN98807359 A CN 98807359A CN 1268636 C CN1268636 C CN 1268636C
Authority
CN
China
Prior art keywords
methyl
alkyl
ethyl
hydrogen atom
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988073595A
Other languages
English (en)
Chinese (zh)
Other versions
CN1264388A (zh
Inventor
B·杰森
T·巴罗萨里
A·浩普特
T·瑟尔克
A·克林格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ai Bowei Germany & Co KG GmbH
Original Assignee
Ebert GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ebert GmbH and Co KG filed Critical Ebert GmbH and Co KG
Publication of CN1264388A publication Critical patent/CN1264388A/zh
Application granted granted Critical
Publication of CN1268636C publication Critical patent/CN1268636C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB988073595A 1997-07-18 1998-07-07 多拉司他汀15衍生物 Expired - Fee Related CN1268636C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives
US08/896,394 1997-07-18

Publications (2)

Publication Number Publication Date
CN1264388A CN1264388A (zh) 2000-08-23
CN1268636C true CN1268636C (zh) 2006-08-09

Family

ID=25406130

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988073595A Expired - Fee Related CN1268636C (zh) 1997-07-18 1998-07-07 多拉司他汀15衍生物

Country Status (32)

Country Link
US (6) US6143721A (cg-RX-API-DMAC7.html)
EP (1) EP0991658B1 (cg-RX-API-DMAC7.html)
JP (4) JP4508413B2 (cg-RX-API-DMAC7.html)
KR (1) KR100579748B1 (cg-RX-API-DMAC7.html)
CN (1) CN1268636C (cg-RX-API-DMAC7.html)
AR (1) AR018501A1 (cg-RX-API-DMAC7.html)
AT (1) ATE314387T1 (cg-RX-API-DMAC7.html)
AU (1) AU750120B2 (cg-RX-API-DMAC7.html)
BG (1) BG65212B1 (cg-RX-API-DMAC7.html)
BR (1) BR9810911A (cg-RX-API-DMAC7.html)
CA (1) CA2296036C (cg-RX-API-DMAC7.html)
CO (1) CO4990967A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107047T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303045B6 (cg-RX-API-DMAC7.html)
DE (1) DE69832982T2 (cg-RX-API-DMAC7.html)
DK (1) DK0991658T3 (cg-RX-API-DMAC7.html)
ES (1) ES2258819T3 (cg-RX-API-DMAC7.html)
HR (1) HRP980397A2 (cg-RX-API-DMAC7.html)
HU (1) HU228996B1 (cg-RX-API-DMAC7.html)
ID (1) ID24669A (cg-RX-API-DMAC7.html)
IL (1) IL133784A (cg-RX-API-DMAC7.html)
MY (1) MY135057A (cg-RX-API-DMAC7.html)
NO (1) NO326827B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ502296A (cg-RX-API-DMAC7.html)
PL (1) PL197884B1 (cg-RX-API-DMAC7.html)
PT (1) PT991658E (cg-RX-API-DMAC7.html)
RU (1) RU2195462C2 (cg-RX-API-DMAC7.html)
SK (1) SK286581B6 (cg-RX-API-DMAC7.html)
TR (2) TR200103545T2 (cg-RX-API-DMAC7.html)
TW (1) TW533217B (cg-RX-API-DMAC7.html)
WO (1) WO1999003879A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA986358B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686336B2 (en) 2000-02-08 2004-02-03 Federal Government As Represented By The Department Of Veterans Affaires N-terminal D(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP5042444B2 (ja) 2002-03-22 2012-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌の処置におけるヘミアスタリン誘導体およびその利用法
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
EP2353611B1 (en) * 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
SG171682A1 (en) 2006-05-16 2011-06-29 Aegera Therapeutics Inc Iap bir domain binding compounds
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
UA106586C2 (uk) 2008-01-31 2014-09-25 Дженентек, Інк. Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
NZ600608A (en) 2009-12-18 2015-01-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
EP3263583A1 (en) 2010-02-12 2018-01-03 Pharmascience Inc. Iap bir domain binding compounds
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
NZ737471A (en) 2015-06-15 2022-02-25 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers for conjugation
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2018086139A1 (en) 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
ES2144421T3 (es) * 1991-08-09 2000-06-16 Teikoku Hormone Mfg Co Ltd Nuevo derivado tetrapeptidico.
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
WO1993017388A1 (en) 1992-02-26 1993-09-02 Clark Paul C System for protecting computers via intelligent tokens or smart cards
JP3523253B2 (ja) * 1992-05-20 2004-04-26 アボット ゲーエムベーハー ウント カンパニー カーゲー ドラスタチン誘導体
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE69329425T2 (de) * 1992-12-16 2001-01-18 Basf Ag Dolastatin analog
US5554993A (en) 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
AU728161B2 (en) 1997-01-10 2001-01-04 Silicon Gaming, Inc. Method and apparatus using geoographical position and a universal time to determination means to provide authenticated, secure, on-line communication between remote gaming locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Also Published As

Publication number Publication date
NO20000231L (no) 2000-01-17
TW533217B (en) 2003-05-21
DE69832982D1 (de) 2006-02-02
IL133784A (en) 2005-09-25
CZ2000176A3 (en) 2001-06-13
MY135057A (en) 2008-01-31
AR018501A1 (es) 2001-11-28
EP0991658A1 (en) 2000-04-12
CO4990967A1 (es) 2000-12-26
HU228996B1 (hu) 2013-07-29
JP2001515010A (ja) 2001-09-18
DK0991658T3 (da) 2006-05-15
SK286581B6 (sk) 2009-01-07
NZ502296A (en) 2002-02-01
US7662786B2 (en) 2010-02-16
SK187999A3 (en) 2000-09-12
JP5122429B2 (ja) 2013-01-16
US20100099843A1 (en) 2010-04-22
PT991658E (pt) 2006-05-31
BR9810911A (pt) 2000-08-01
JP5047935B2 (ja) 2012-10-10
AU8475898A (en) 1999-02-10
TR200103545T2 (tr) 2002-06-21
TR200000132T2 (tr) 2000-05-22
CA2296036C (en) 2007-05-01
HRP980397A2 (en) 1999-04-30
KR20010021998A (ko) 2001-03-15
BG65212B1 (bg) 2007-07-31
NO20000231D0 (no) 2000-01-17
EP0991658B1 (en) 2005-12-28
US20030153505A1 (en) 2003-08-14
BG104089A (en) 2000-12-29
JP4508413B2 (ja) 2010-07-21
US20130046077A1 (en) 2013-02-21
US6143721A (en) 2000-11-07
IL133784A0 (en) 2001-04-30
RU2195462C2 (ru) 2002-12-27
ES2258819T3 (es) 2006-09-01
US6458765B1 (en) 2002-10-01
WO1999003879A1 (en) 1999-01-28
KR100579748B1 (ko) 2006-05-15
US8163698B2 (en) 2012-04-24
ATE314387T1 (de) 2006-01-15
AU750120B2 (en) 2002-07-11
HUP0004234A2 (hu) 2001-05-28
PL338144A1 (en) 2000-09-25
CN1264388A (zh) 2000-08-23
JP2012211164A (ja) 2012-11-01
CY1107047T1 (el) 2012-09-26
DE69832982T2 (de) 2006-08-24
JP2009137967A (ja) 2009-06-25
US7084110B2 (en) 2006-08-01
PL197884B1 (pl) 2008-05-30
HK1029125A1 (en) 2001-03-23
ZA986358B (en) 2000-01-17
CA2296036A1 (en) 1999-01-28
CZ303045B6 (cs) 2012-03-07
NO326827B1 (no) 2009-02-23
US20060270606A1 (en) 2006-11-30
ID24669A (id) 2000-07-27
HUP0004234A3 (en) 2001-08-28
JP2009137968A (ja) 2009-06-25

Similar Documents

Publication Publication Date Title
CN1268636C (zh) 多拉司他汀15衍生物
CN1057095C (zh) 新型肽,其制备及应用
CN1182153C (zh) 新的多拉抑放素衍生物及其制备方法和用途
CN1203090C (zh) 环化粘合抑制剂
CN1065874C (zh) 新的肽及其制备和应用
CN1134148A (zh) 抗血栓形成的脒基苯丙氨酸和脒基吡啶丙氨酸的衍生物
CN1451017A (zh) 选择性环肽
CN1852920A (zh) 丝氨酸蛋白酶抑制剂、特别是hcvns3－ns4a蛋白酶抑制剂
CN86101850A (zh) N，n′-二烷基胍基二肽的制造方法与用途
HK1048642B (zh) Fap活化的抗肿瘤化合物
CN1171118A (zh) 纤连蛋白粘附抑制剂
CN1313863A (zh) 尿激酶和血管形成的抑制剂
CN1041950A (zh) 新型肽酶抑制剂
CN1100104A (zh) 新的多肽化合物及其制备方法
CN1311796A (zh) 肽类抗血管生成药
CN1252806A (zh) 在c端具有羰基和杂环官能团的多拉司他汀－15衍生物
CN1181092C (zh) 可用于治疗前列腺癌的缀合物
CN1099040A (zh) 线性粘合抑制剂
CN1150028C (zh) 三-、四-、五-和多肽以及它们作为抗抑郁剂的治疗应用
CN1157223C (zh) 多拉司他汀-15衍生物与紫杉烷的组合
CN1054857C (zh) 具有胃肠道运动刺激活性的胃动素样多肽
CN1086825A (zh) 三环和四环化合物
CN1278734A (zh) 用于治疗类风湿性关节炎的方法和组合物
CN1282337A (zh) 具有整联蛋白抑制剂特性的环肽衍生物
CN1189477C (zh) 二环速激肽拮抗剂,其制备和在药物组合物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: AVECIA BIOLOGY TECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: BASF AKTIENGESELLCHAFT

Effective date: 20030813

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030813

Address after: Wiesbaden

Applicant after: Ebert GmbH & Co. KG

Address before: Ludwigshafen, Germany

Applicant before: Basf AG

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ABBVIE GERMANY GMBH + CO., KG.

Free format text: FORMER OWNER: EBERT GMBH + CO. KG

Effective date: 20140401

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140401

Address after: Wiesbaden

Patentee after: Ai Bowei Germany GmbH & Co Kg

Address before: Wiesbaden

Patentee before: Ebert GmbH & Co. KG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060809

Termination date: 20150707

EXPY Termination of patent right or utility model